QualityStocksNewsBreaks – Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) Reports $2.89 Million in Q3 Revenue Following Technology Business Transition
Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) reported financial results for the third quarter ended Sept. 30, 2026, including revenue of $2.89 million, compared with no revenue a year earlier, marking its first full quarter of revenue from its technology business. The company generated $2.48 million from software development and deployment services for two enterprise customers, including one related party. Operating income totaled $2 million, while net income reached $33.6 million, or $19.13 per basic share, including a $25.26 million unrealized gain on digital assets. Total assets stood at $153.5 million, with shareholders' equity of $140.5 million. Apimeds completed its…